# Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer

> **NCT00170573** · PHASE2 · COMPLETED · sponsor: **North Eastern German Society of Gynaecological Oncology** · enrollment: 77 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Caelyx

## Key facts

- **NCT ID:** NCT00170573
- **Lead sponsor:** North Eastern German Society of Gynaecological Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-09
- **Primary completion:** 2009-04
- **Final completion:** 2010-08
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2024-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00170573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00170573, "Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00170573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*